Shepard K V, Larson R, Le Beau M M, Leichman L, Levin B
Department of Medicine, University of Chicago, Illinois.
Invest New Drugs. 1988 Jun;6(2):121-4. doi: 10.1007/BF00195370.
Secondary acute leukemias can occur in patients who have been treated with chemotherapy. Several reports have shown that treatment with nitrosoureas can result in secondary leukemia, but this is the first report implicating the investigational drug PCNU as a cause. This case is unique because of the cytogenetic findings, the short latency period between the chemotherapy and the diagnosis of leukemia, and the successful treatment of the leukemia with high-dose cytarabine (ara-C).
继发性急性白血病可发生于接受过化疗的患者。多项报告显示,亚硝基脲治疗可导致继发性白血病,但这是首例将研究药物PCNU列为病因的报告。该病例具有独特性,原因在于细胞遗传学检查结果、化疗与白血病诊断之间较短的潜伏期,以及采用大剂量阿糖胞苷(ara-C)成功治愈白血病。